Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Drug metabolism and drug interactions - 1 Jan 2012

Dorado Pedro, Machín Esther, de Andrés Fernando, Naranjo María-Eugenia, Peñas-Lledó Eva M, Llerena Adrián

Abstract excerpt

BACKGROUND: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochrome CYP2C9. The aim of the study was to develop a high-performance liquid chromatographic (HPLC) method with fluorescence detection for simultaneously measuring losartan and its metabolite E-3174 in urine to evaluate the losartan urinary metabolic ratio (MR: losartan/E-3174) for CYP2C9 phenotyping in humans....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Cytochrome P-450 CYP2C9

Share to Hydroxylation

Share to Imidazoles

Share to Losartan

Share to Tetrazoles

Source

Identifiers

PMID: 23093260
DOI: 10.1515/dmdi-2012-0018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.PMID 23093260Read ↗

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.Semantic proximity Read ↗

Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.Semantic proximity Read ↗

CYP2C9 genetic variants and losartan oxidation in a Turkish population.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.Semantic proximity Read ↗

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.Semantic proximity Read ↗

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Semantic proximity Read ↗

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.Semantic proximity Read ↗

Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers.Semantic proximity Read ↗

Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.Semantic proximity Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.